SEC Comment Letter 0000000000-24-001600 to LENZ Therapeutics, Inc. (LENZ)
LENZ Therapeutics, Inc.
Date: Feb. 9, 2024 · CIK: 0001815776 · Accession: 0000000000-24-001600
AI Filing Summary & Sentiment
File numbers found in text: 333-275919
Letter
United States securities and exchange commission logo February 9, 2024 Kimberlee Drapkin Chief Executive Officer Graphite Bio, Inc. 611 Gateway Blvd, Suite 120 South San Francisco, CA 94080 Re:Graphite Bio, Inc. Amendment No. 3 to Registration Statement on Form S-4 Filed February 5, 2024 File No. 333-275919 Dear Kimberlee Drapkin: We have reviewed your amended registration statement and have the following comment. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe a comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to this letter, we may have additional comments. Amendment No. 3 to Registration Statement on Form S-4 filed February 5, 2024 Litigation Related to the Merger, page 23 1.Please provide the disclosures required by Item 103 of Regulation S-K, including, for example only, the relief sought. Please contact Eric Atallah at 202-551-3663 or Lynn Dicker at 202-551-3616 if you have questions regarding comments on the financial statements and related matters. Please contact Doris Stacey Gama at 202-551-3188 or Jason Drory at 202-551-8342 with any other questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Andrew Goodman, Esq.
Show Raw Text
United States securities and exchange commission logo
February 9, 2024
Kimberlee Drapkin
Chief Executive Officer
Graphite Bio, Inc.
611 Gateway Blvd, Suite 120
South San Francisco, CA 94080
Re:Graphite Bio, Inc.
Amendment No. 3 to Registration Statement on Form S-4
Filed February 5, 2024
File No. 333-275919
Dear Kimberlee Drapkin:
We have reviewed your amended registration statement and have the following comment.
Please respond to this letter by amending your registration statement and providing the
requested information. If you do not believe a comment applies to your facts and circumstances
or do not believe an amendment is appropriate, please tell us why in your response.
After reviewing any amendment to your registration statement and the information you
provide in response to this letter, we may have additional comments.
Amendment No. 3 to Registration Statement on Form S-4 filed February 5, 2024
Litigation Related to the Merger, page 23
1.Please provide the disclosures required by Item 103 of Regulation S-K, including, for
example only, the relief sought.
Please contact Eric Atallah at 202-551-3663 or Lynn Dicker at 202-551-3616 if you have
questions regarding comments on the financial statements and related matters. Please contact
Doris Stacey Gama at 202-551-3188 or Jason Drory at 202-551-8342 with any other questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Andrew Goodman, Esq.